Most Favored Patient Act of 2026
Sponsored By: Representative Meuser, Daniel [R-PA-9]
Introduced
Summary
Mandates a Most Favored Nations drug pricing test for Medicare and Medicaid populations. This bill would direct the Center for Medicare and Medicaid Innovation to run a five-year Most Favored Nations (MFN) Pricing Model starting January 1, 2029, that ties U.S. prices for covered drugs to the second-lowest net price among eight reference countries and requires reporting and possible U.S. manufacturing commitments for covered agreements.
Show full summary
- Medicare and Medicaid patients and their providers would be eligible to receive covered drugs at the MFN price when they meet the bill's eligibility rules. The MFN price is defined as the second-lowest applicable net price across eight reference countries.
- Specified drug manufacturers would have to provide access to MFN prices and report sales and pricing data to the Secretary to calculate MFN prices. Manufacturers could instead enter a "covered agreement" that must be in place by December 31, 2028 and that includes commitments to expand U.S. manufacturing.
- The Center for Medicare and Medicaid Innovation would test the MFN model for five years beginning in 2029. The Secretary may suspend MFN requirements for a specific drug until April 1, 2029 if a covered agreement is likely.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Lower drug prices for Medicare and Medicaid
If enacted, CMMI would test a Most-Favored-Nations drug pricing model starting January 1, 2029. The model would run for five years. Manufacturers without a covered agreement would have to give Medicare and Medicaid-eligible patients access to the MFN price. Pharmacies and providers serving those patients would also get MFN-price access. Manufacturers would have to report price data the Secretary specifies. The MFN price would be the second-lowest net price across Canada, Denmark, France, Germany, Italy, Japan, Switzerland, and the United Kingdom. The Secretary could pause the MFN rule for a drug until April 1, 2029 if a manufacturer is likely to sign a covered agreement. Covered agreements must be entered by December 31, 2028 and reported to Congress by April 1, 2029, or within 30 days after enactment if the agreement existed earlier.
Sponsors & CoSponsors
Sponsor
Meuser, Daniel [R-PA-9]
PA • R
Cosponsors
There are no cosponsors for this bill.
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov